ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KROS vs PYXS // EV/EBITDA & P/E VALUATION

Keros Therapeutics Inc. (NASDAQ) VS. Pyxis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: KROS 6 — PYXS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KROS VS. PYXS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KROS PYXS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 82.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 KROS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin 27.70% -60.00% +87.70 KROS /operating-margins <GO>
Net Profit Margin 35.70% -60.00% +95.70 KROS /net-margins <GO>
Revenue Growth (YoY) 180.00% -14.20% +194.20 KROS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.31 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 3/9 +5.00 KROS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.6 34.8 +5.76 KROS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $225.2M $226.0M -$776.2K PYXS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KROS REV PYXS REV KROS GROSS % PYXS GROSS % KROS FCF PYXS FCF
FY 2025 $244.1M $13.9M — 82.8% $106.0M -$63.5M
FY 2024 $3.5M $16.1M — 97.1% -$162.8M -$57.9M
FY 2023 $151.0K $0 — — -$124.5M -$70.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KROS // BETA —
PYXS // BETA —